MX2010004975A - Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa. - Google Patents

Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa.

Info

Publication number
MX2010004975A
MX2010004975A MX2010004975A MX2010004975A MX2010004975A MX 2010004975 A MX2010004975 A MX 2010004975A MX 2010004975 A MX2010004975 A MX 2010004975A MX 2010004975 A MX2010004975 A MX 2010004975A MX 2010004975 A MX2010004975 A MX 2010004975A
Authority
MX
Mexico
Prior art keywords
lactose
carriers
combination
oral contraceptive
gestagen
Prior art date
Application number
MX2010004975A
Other languages
English (en)
Inventor
Beate Burglen
Manuela Pfeifer
Sabine Fricke
Claus Claussen
Ralf Ladwig
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2010004975A publication Critical patent/MX2010004975A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Los gestágenos, con preferencia dienogest, acetato de clormadinona o levornogetrel en combinación con estrógenos tales como, por ejemplo, etinilestradiol, 17ß-estradiol o valerato de estradiol y uno o varios excipientes/portadores farmacéuticamente aceptables realizan una anticoncepción oral sin lactosa. Se da una posibilidad para mejorar la prevención de la intolerancia a la glucosa en un factor que eventualmente contribuye con la mejoría, incluso en cuanto a costosos ensayos de la intolerancia a la glucosa. La invención también es apropiada para un uso prolongado.
MX2010004975A 2007-11-05 2008-10-22 Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa. MX2010004975A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07021465A EP2055306A1 (de) 2007-11-05 2007-11-05 Verwendung eines Gestagens in Kombination mit einem Estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/Trägern zur laktosefreien oralen Kontrazeption
PCT/EP2008/008900 WO2009059690A1 (de) 2007-11-05 2008-10-22 Verwendung eines gestagens in kombination mit einem estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/ trägern zur laktosefreien oralen kontrazeption

Publications (1)

Publication Number Publication Date
MX2010004975A true MX2010004975A (es) 2010-05-24

Family

ID=39016019

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004975A MX2010004975A (es) 2007-11-05 2008-10-22 Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa.

Country Status (31)

Country Link
EP (3) EP2055306A1 (es)
JP (1) JP2011502136A (es)
KR (1) KR20100103794A (es)
CN (1) CN101848716B (es)
AR (1) AR069195A1 (es)
AT (1) AT12800U1 (es)
AU (1) AU2008324549A1 (es)
BR (1) BRPI0819189A2 (es)
CA (1) CA2704523A1 (es)
CO (1) CO6270329A2 (es)
CR (1) CR11413A (es)
DE (1) DE202007019049U1 (es)
DK (1) DK2217243T3 (es)
DO (1) DOP2010000130A (es)
EA (1) EA201000749A1 (es)
EC (1) ECSP10010152A (es)
ES (1) ES2511841T3 (es)
HK (1) HK1145289A1 (es)
HR (1) HRP20140962T1 (es)
IL (1) IL205349A0 (es)
MX (1) MX2010004975A (es)
NZ (1) NZ585065A (es)
PA (1) PA8803001A1 (es)
PE (1) PE20091020A1 (es)
PL (1) PL2217243T3 (es)
PT (1) PT2217243E (es)
SG (1) SG188118A1 (es)
TW (1) TW200936142A (es)
UY (1) UY31454A1 (es)
WO (1) WO2009059690A1 (es)
ZA (1) ZA201004024B (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368373A1 (en) * 1988-10-13 1990-05-16 Akzo Nobel N.V. Multi-phase contraceptive preparation
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JPH1171268A (ja) * 1997-08-28 1999-03-16 Kayaku:Kk 性ホルモン含有錠剤
CA2260673A1 (en) 1999-02-04 2000-08-04 Natrel Inc. A process for making a lactose-free milk without negatively affecting the organoleptic properties thereof; and milk so processed
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
FR2832065B1 (fr) * 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
AU2004275470B2 (en) 2003-09-29 2010-12-02 Novo Nordisk Health Care Ag Improved stability of progestogen formulations
WO2005030175A1 (en) 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Hrt formulations
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
DE102004019406A1 (de) * 2004-04-19 2005-11-03 Schering Ag 17α-Fluorsteroide
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
EP1690543A1 (de) * 2005-02-15 2006-08-16 Schering AG Pharmazeutisches Präparat zur Kontrazeption
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest

Also Published As

Publication number Publication date
DK2217243T3 (da) 2014-10-20
CN101848716B (zh) 2012-11-28
CN101848716A (zh) 2010-09-29
EA201000749A1 (ru) 2010-12-30
BRPI0819189A2 (pt) 2015-05-26
AT12800U1 (de) 2012-11-15
CR11413A (es) 2010-06-17
PE20091020A1 (es) 2009-08-15
EP2217243B1 (de) 2014-08-06
HRP20140962T1 (hr) 2014-12-05
CO6270329A2 (es) 2011-04-20
PL2217243T3 (pl) 2014-12-31
AR069195A1 (es) 2010-01-06
ECSP10010152A (es) 2010-06-29
UY31454A1 (es) 2009-05-29
DE202007019049U8 (de) 2010-09-30
ZA201004024B (en) 2012-11-28
WO2009059690A1 (de) 2009-05-14
SG188118A1 (en) 2013-03-28
IL205349A0 (en) 2010-12-30
DE202007019049U1 (de) 2010-05-12
HK1145289A1 (en) 2011-04-15
DOP2010000130A (es) 2010-07-31
PA8803001A1 (es) 2009-06-23
ES2511841T3 (es) 2014-10-23
EP2217243A1 (de) 2010-08-18
KR20100103794A (ko) 2010-09-28
EP2774614A1 (de) 2014-09-10
NZ585065A (en) 2012-06-29
CA2704523A1 (en) 2009-05-14
AU2008324549A1 (en) 2009-05-14
PT2217243E (pt) 2014-09-24
TW200936142A (en) 2009-09-01
EP2055306A1 (de) 2009-05-06
JP2011502136A (ja) 2011-01-20

Similar Documents

Publication Publication Date Title
Schindler The “newer” progestogens and postmenopausal hormone therapy (HRT)
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
EP2108652A3 (en) Process for the preparation of drospirenone
PL2131847T3 (pl) Lek zawierający przynajmniej jeden gestagen
MX2010004353A (es) Combinación anticonceptiva oral entiemética.
BR112012009306A2 (pt) método para regeneração de mielina em um paciente
RS50972B (sr) Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
EP2433951A3 (en) A process for the preparation of drospirenone
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
JP2008515909A5 (es)
MX2022012917A (es) Composiciones anticonceptivas con efectos adversos reducidos.
RS90504A (en) C-17 spirolactonization and 6,7 oxidation of steroids
MX2010004975A (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa.
WO2008017658A3 (en) Use of glucocorticoid receptor antagonists for treatment of infectious conditions
SI1635843T1 (sl) Terapija, ki vsebuje dienogest, za hormonsko nadomestitev in depresijo
PL1978970T3 (pl) Środek antykoncepcyjny
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
CU20100084A7 (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
CR11211A (es) Estratienos 8-beta-sustituidos como estrogenos de accion selectiva
MX2009007259A (es) Preparacion farmaceutica para reducir la endometriosis.
SI1886694T1 (sl) Peroralna medikamentna oblika z dienogestom in etinilestradiolom za kontracepcijo
UY29860A1 (es) Procedimiento para la producción de una preparación farmacéutica monofásica para la terapia oral de la hemorragia uterina disfuncional
TH124135A (es)
UA97960C2 (ru) ПРИМЕНЕНИЕ ЭСТРАДИОЛА ВАЛЕРАТА ИЛИ 17β-ЭСТРАДИОЛА В КОМБИНАЦИИ С ДИЕНОГЕСТОМ ДЛЯ ПЕРОРАЛЬНОГО ЛЕЧЕНИЯ ДЛЯ ПОДДЕРЖАНИЯ И/ИЛИ ПОВЫШЕНИЯ ПОЛОВОГО ВЛЕЧЕНИЯ У ОСОБИ ЖЕНСКОГО ПОЛА
PL1910398T3 (pl) 17-alfa-podstawione pochodne estradiolu wykazujące działanie gojenia ran

Legal Events

Date Code Title Description
FA Abandonment or withdrawal